Barclays has initiated coverage on Align Technology Inc (ALGN) with an Equal-Weight rating, marking its first assessment of the company. This rating reflects the firm's analysis of Align's business dynamics and growth prospects within the health care sector.
Align Technology, headquartered in Tempe, Arizona, specializes in designing and manufacturing orthodontic and aesthetic dentistry products. The company is known for its Align Digital Platform and operates primarily through two segments: Clear Aligner and Imaging Systems and CAD/CAM Services. The Clear Aligner segment includes comprehensive products like Invisalign Comprehensive and Invisalign First, along with retention products and training tools.
As of December 8, 2025, Align Technology's stock is priced at $162.42, with a market capitalization of $11.6 billion and a trailing twelve-month price-to-earnings ratio of 30.65. The company is scheduled to report its next earnings on July 28, 2026, with earnings per share estimated at $2.74 and revenue projected at $1.1 billion.
Analyst ratings provide insights based on extensive research and financial modeling. They can serve as one of many considerations for investors, alongside company fundamentals and market trends. Given the evolving nature of analyst opinions, these ratings may change as new information becomes available.
As of December 1, 2025, the consensus among analysts for Align Technology stands at 7 Strong Buy, 7 Buy, 8 Hold, 1 Sell, and 0 Strong Sell, indicating a general positive outlook among financial experts.